ONCOZENGE Aktie

 

OncoZenge AB (publ) (”OncoZenge” or “the Company”) announces that the Company's board member and Chief Medical Officer Dr. Chris Nowak, will present the study design for the planned registrational Phase 3 study of BupiZenge™ at the Multinational Association of Supportive Care in Cancer (MASCC) / International Society of Oral Oncology (ISOO) Annual Meeting 2025 in Seattle, Washington, USA. The study aims to compare BupiZenge™ with the current standard of care for treating pain caused by oral mucositis in cancer patients. The oral presentation will take place within the Cancer Pain section on...

OncoZenge AB (publ) ("OncoZenge" or the “Company") has today received confirmation that the Department of Commerce has issued a certificate of approval for the investment agreement entered into by the Company and Sichuan-Yangtian Biopharmaceuticals Co, Ltd (“Yangtian Pharma” or the “Investor”) on January 27th, 2025. On January 27th the Company announced the intention to partner with Yangtian Pharma as a new strategic investor in the Company, by entering into an investment agreement that through four tranches of directed share issues to Yangtian Pharma will provide the financing for the phase...

OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces that LINK Medical has been engaged to conduct a feasibility study in Europe for the Company's planned Phase 3 study for European approval of BupiZenge™. OncoZenge is planning a multi-country Phase 3 study for the approval of BupiZenge™ in Europe. The scope of the Phase 3 study has been updated in recent weeks in close collaboration with the Company's licensing partner, Molteni Farmaceutici. As part of the planning and to optimize lead-times, the Company has engaged LINK Medical to perform a feasibility study for the European...

OncoZenge AB (publ) ("OncoZenge" or the “Company") today provides an update on the status of the regulatory process in China for the investment agreement entered into by the Company and Sichuan-Yangtian Biopharmaceuticals Co, Ltd (“Yangtian Pharma” or the “Investor”) on January 27th, 2025. The filing is currently in review with the provincial Department of Commerce, and the necessary documentation has been provided to the counterparty bank appointed by the State Administration of Foreign Exchange. On January 27th the Company announced the intention to partner with Yangtian Pharma as a new...

OncoZenge AB (publ) ("OncoZenge" or the “Company") has today received confirmation that the NDRC has issued a certificate of approval for the investment agreement entered into by the Company and Sichuan-Yangtian Biopharmaceuticals Co, Ltd (“Yangtian Pharma” or the “Investor”) on January 27th, 2025. On January 27th the Company announced the intention to partner with Yangtian Pharma as a new strategic investor in the Company, by entering into an investment agreement that through four tranches of directed share issues to Yangtian Pharma will provide the financing for the phase 3 trial for...

OncoZenge AB (publ) ("OncoZenge" or the “Company") today provides an update on the status of the regulatory process in China for the investment agreement entered into by the Company and Sichuan-Yangtian Biopharmaceuticals Co, Ltd (“Yangtian Pharma” or the “Investor”) on January 27th, 2025. Following amendments NDRC has accepted the completeness of the investor's filing, and a subsequent filing has been made with Ministry of Commerce. On January 27th the Company announced the intention to partner with Yangtian Pharma as a new strategic investor in the Company, by entering into an investment...

OncoZenge AB (publ) [”OncoZenge” or the "Company”] announces that the Company and Avernus Pharma General Trading LLC (“Avernus”), a pharma marketing company from the UAE, have signed an exclusive agreement to license BupiZenge™ (Bupivacaine oral lozenges) for commercialization and distribution in the Gulf Cooperation Council (GCC) region. Background The licensing agreement entails that Avernus will be the exclusive distributor of BupiZenge™ in the GCC region, including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the UAE, pending successful completion of the BupiZenge™ phase 3 trial and...

OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces receipt of the initial milestone payment from Molteni Farmaceutici On March 28, 2025, OncoZenge announced that the Company had entered an agreement granting Molteni Farmaceutici exclusive rights and for a commercial partnership to introduce BupiZenge™ in Europe (EU27, EEA, Switzerland, and United Kingdom). The agreement includes, among other, milestone payments of EUR 250,000 upon execution of the agreement and EUR 250,000 at the successful completion of the planned clinical phase III study. The initial milestone...

OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces the reinforcement of its Phase 3 sponsor team for BupiZenge™ to manage regulatory affairs. OncoZenge is pleased to announce that Christina Junvik is joining the Company through an expanded collaboration with PharmaRelations to enhance the Company's preparedness for the Phase 3 project with BupiZenge™. Christina will be responsible for the planning and coordination of regulatory activities and relevant documentation for interactions with authorities. She will also join the sponsor oversight team for the Company's Phase 3...

Stockholm, Sweden – April 2 2025 – OncoZenge AB (publ) today announces its participation at the 2025 Multinational Association of Supportive Care in Cancer (MASCC) annual meeting taking place in Seattle, USA, on June 26-28, 2025, where Dr. Christoph Nowak will present an abstract on the company's European Phase 3 study for BupiZenge™. The MASCC annual meeting is a premier gathering of healthcare professionals dedicated to improving the quality of life for cancer patients. The conference focuses on the latest advancements and best practices in cancer supportive care. OncoZenge will be...

OncoZenge AB (publ) (“OncoZenge” or the “Company”) announces that the Company has entered into a binding agreement to partner with L. Molteni & C. dei F.lli Alitti, Società di Esercizio S.p.A (“Molteni Farmaceutici”) regarding exclusive rights to commercialization of BupiZenge™ in Europe. The agreement includes customary royalties on sales and commercial milestone payments. On January 13, 2025, OncoZenge announced that the Company had entered into a non-binding agreement with the intention to partner with Molteni Farmaceutici for the commercialization of BupiZenge™ in Europe. In line with...

Stockholm, March 4, 2025 – OncoZenge AB (publ) announces today that a positive opinion has been received regarding the patentability of the new international application submitted to the PCT (Patent Cooperation Treaty) earlier this year. A positive international preliminary examination report and a written opinion have been issued by the PCT (Patent Cooperation Treaty) authority. The patent application is directed to patent claims related to the product, and fulfills the patentability criteria. The next step is to submit the application in the countries and regions the company prioritizes...

OncoZenge AB (publ) (“OncoZenge” or the “Company”) announces that the Company has entered into an investment agreement (the “Investment Agreement”)whereby the Chinese investor Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the “Investor”) has undertaken to subscribe for a maximum of 4,669,647 new shares in the Company at a subscription price of SEK 6.47 per share, which represents a premium of approximately 40 percent compared to the volume-weighted average price (VWAP) for the Company's shares on Nasdaq First North Growth Market during a period of 20 trading days ending on 24 January 2025, and...

STOCKHOLM, SWEDEN - January 16, 2025 – OncoZenge AB (publ) (“OncoZenge” or the “Company”), announces the filing of a patent application under the Patent Cooperation Treaty (PCT) process, a significant milestone in the intellectual property strategy for the company's lead drug candidate, BupiZenge™. This filing follows the patent application submitted with priority with the Swedish Patent and Registration Office (PRV) in February of 2024, in line with international PCT requirements. The PCT process is a crucial step toward obtaining broad international patent protection, offering the...

STOCKHOLM, SWEDEN – January 13, 2025 – OncoZenge AB (publ) (“OncoZenge” or the “Company”), announces that the Company has entered into a non-binding agreement with the intention to partner with pharmaceutical leader Molteni Farmaceutici (“Molteni”) regarding exclusive rights to commercialization of BupiZenge™ in Europe. The Company has signed a non-binding offer from Molteni for a commercial partnership to introduce BupiZenge™ in Europe with the goal to sign the definitive licensing agreement no later than April 30th, 2025. During a period of exclusivity, the parties will complete planning,...

STOCKHOLM, SWEDEN – October 18, 2024 – OncoZenge AB (publ) (“OncoZenge” or the “Company”), announces the intention to partner with the global pharmaceutical leader Pharmanovia regarding exclusive rights to commercialization of BupiZenge™ in Europe, the Middle East, and Northern Africa (the “EMENA region”). The Company has signed a non-binding offer from Pharmanovia for a commercial partnership to introduce BupiZenge™ in Europe, the Middle East and Northern Africa. The parties will now enter a period of exclusivity to complete detailed due diligence and joint detailed planning, with the goal...

Stockholm, Sweden – June 4 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces its participation in the 2024 Multinational Association of Supportive Care in Cancer (MASCC) annual meeting taking place in Lille, France on June 27-29, 2024. The MASCC annual meeting is a premier gathering of healthcare professionals dedicated to improving the quality of life for cancer patients. Consistent with MASCC's purpose the conference focuses on the latest advancements and best practices in cancer supportive...